GIM
GMAB icon

Glenmede Investment Management’s Genmab GMAB Stock Holding History

Glenmede Investment Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$434K Buy
14,137
+278
+2% +$6.78K ﹤0.01% 982
2025
Q2 		$286K Buy
+13,859
New +$284K ﹤0.01% 1121

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Investment Management's GMAB Position: Q3 2025 in Review

Glenmede Investment Management increased its Genmab (GMAB) stake by 2% in Q3 2025, buying an estimated $6.78K and bringing the position to 14,137 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

Glenmede Investment Management first reported a position in GMAB in Q2 2025 and has held it in 2 quarters since. 253 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

  • Glenmede Investment Management held 14,137 shares of Genmab worth $434K as of Q3 2025.
  • Glenmede Investment Management bought 278 Genmab shares in Q3 2025, an estimated $6.78K.
  • Genmab made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #982 holding.
  • Glenmede Investment Management first reported a position in Genmab in Q2 2025 and has held it in 2 quarters since.
  • 253 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.